The FDA has approved a new drug called Idelivon, which is created for children and adults who suffer from Hemophilia B. Hemophilia B is a rare blood disorder that prevents blood from clotting naturally. This disease is a rare inherited trait found in men. It is highly unlikely for a woman to have Hemophilia B. Idelivon drug is the first coagulation factor-albumin fusion protein product to be approved.
“The approval of Idelvion provides another important therapeutic option for children and adults with Hemophilia B to help prevent or control bleeding and reduce the frequency of bleeding episodes,” said Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research. Marks has an M.D. and Ph.D.
The newly approved drug was created to replace Factor XI, a clotting factor that occurs naturally that is missing in Hemophilia B victims. The safety of this new medication was evaluated in two multicenter studies. Idelivon has proven to control excessive bleeding and the worst side effect is known to be a headache.
For more information, click here.